ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) (CVE:IPA) said Tuesday that it has acquired additional integrated laboratory equipment for high-throughput antibody screening.
The Victoria, British Columbia, biotech company said in a statement that its purchase of a second Intellicyt iQue Screener PLUS allows its scientists to reduce lead discovery time while conserving samples and reducing reagent cost.
Other antibody screeners, according to the company, report on binding one target at a time, which makes the discovery process time-consuming and can require large amounts of target protein.
"The decision to acquire a second Intellicyt iQue will further support IPA's strategic vision of continued growth and expansion in providing end-to-end therapeutic antibody discovery services to a rapidly expanding list of pharma and biotech clients," said CEO Jennifer Bath in a statement.
The company operates globally to offer antibody services from target analysis to pre-clinical studies. It works out of labs in Victoria as well as in Utrecht and Oss in the Netherlands.
Shares traded at C$0.68 in Monday’s Canadian trading. They were down US$0.04 to US$0.51 on the OTC Markets.
Contact Dennis Fitzgerald at [email protected]